论文部分内容阅读
抗生素是临床上广泛应用的一类重要化疗药物。其中β-内酰胺类抗生素的发展更是可观。据1986年统计,这类药物的世界消费量占世界抗生素消费量的58%,而日本β-内酰胺的销售额占抗生素总额的83%。从目前国外β-内酰胺抗生素研究情况来看,世界各大医药公司规划发展的β-内酰胺抗生素中,以非典型的β内酰胺抗生素为最多,其次为头孢菌素类,青霉素类最少。但是,在80年代中期仍以头孢菌素类为最多,它仍保持着领先的地位,发展的品种和产量都在急剧增长。
Antibiotics are a class of important chemotherapeutic drugs widely used clinically. The development of β-lactam antibiotics is even more impressive. According to 1986 statistics, world consumption of such drugs accounted for 58% of world antibiotic consumption, while Japan’s β-lactam accounted for 83% of total antibiotic sales. From the current situation of β-lactam antibiotics abroad, among the β-lactam antibiotics planned and developed by major pharmaceutical companies in the world, the most typical is β-lactam antibiotics, followed by cephalosporins and the least penicillins. However, cephalosporins remained the most dominant species in the mid-1980s and maintained a leading position in the development and variety of varieties and yields.